Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC-derived Pleiotropic Factor for Donor Sites
NCT04234750Phase 1Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Biologic, CFT (Cell-free therapy)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mesenchymal stem cell-derived pleiotropic factor in skin graft donor-site wound (SGDW) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Wound healing rate at 1 month. Status: unknown.
02
Drugs
mesenchymal stem cell-derived pleiotropic factor
03
Conditions
skin graft donor-site wound (SGDW)
Beyond the preview
Go deeper on NCT04234750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04234750.